Glaxo cancer drugs given European greenlight

<div><p>European regulators on Friday recommended GlaxoSmithKline PLC's kidney cancer drug Votrient for conditional marketing authorization and also backed the wider use of the company's breast cancer drug Tyverb.</p><p>Decisions by the European Medicines Agency are usually endorsed formally by the European Commission, the European Union's executive body, within a couple of months.</p><p>The conditional decision on Votrient, which is designed to treat advanced renal cell carcinoma, means that it will be reviewed by the EMA in a year. The agency has said it wants to see a comparison with Pfizer's Sutent.</p><p>The EMA said that Tyverb, which is sold as Tykerb in the United States, should be approved for use in combination with an aromatase inhibitor in some breast cancer patients.</p><img src="http://admatch-syndication.mochila.com/images/ad.gif?aid=69712282&bid=informcom" /></div><div id="copyright"><div>

Copyright 2010  <a href="http://www.ap.org">AP Features</a></div></div>